Charitable funding of congenital heart surgery in China: A cost-effectiveness analysis from the National Center for Cardiovascular Diseases Authors: Qiyu He, Xinjie Lin, Tao Lei, Zheng Dou, Jingxuan Xia, Yuze Liu, Yanbing Ma, Kai Ma, Keming Yang, Benqing Zhang, Lu Rui, Marcelo Cardarelli, Shoujun Li Published: 2026 ABSTRACT ObjectivesHumanitarian program has emerged as a critical support mechanism for the management of congenital heart disease (CHD), yet its cost-effectiveness at the hospital level receives little investigation.MethodsWe reviewed 2759 patients underwent CHD surgery at Fuwai Hospital, National Center for Cardiovascular Diseases from 2012 to 2022, and received financial aid from nongovernmental organizations. Analyzed data included baseline characteristics, surgical complexity, hospitalization costs, nongovernmental organization funding proportions, and disability-adjusted life years (DALYs) averted. Cost-effectiveness was calculated as funding expenditure per DALY averted, with adjustments for natural disease history and surgical outcomes.ResultsCharitable fundings covered a median of 31% of hospitalization costs (¥36,564.34/USD $5424.98 per patient), averting 50.82 DALYs per patient at a cost of ¥952.19 ($141.27) per DALY. Neonates and complex CHD cases showed higher number of DALYs averted (59.44 and 54.42, respectively) but lower charitable funding proportions (24% and 32%, respectively). Patients with single-ventricle physiology and patients with previous surgeries exhibited relatively lower cost-effectiveness (¥1627.30 and ¥1349.08 per DALY). Unexpected reinterventions correlated with higher in-hospital mortality (9.6% vs 1%) and lower funding support (19% vs 33%).ConclusionsCharitable funding reduces financial barriers for surgical CHD treatment in China, demonstrating high cost-effectiveness. Funding models should evolve to incorporate surgical complexity and patient age, ensuring more reasonable support in the future. More importantly, the demonstrated cost-effectiveness should encourage more organizations to join the effort of funding CHD surgery, which is the most pivotal action at present. Flowchart of a patient being funded. Central MessageCharitable funding supported approximately 31% of the total hospitalization costs, contributing to an average DALYs averted of 50.82, with a cost-effectiveness of ¥952.19 ($141.27) per DALY averted. PerspectiveCharitable funding in China alleviates financial barriers to CHD treatment, proving its cost-effectiveness. The demonstrated cost-effectiveness should encourage more organizations to join the effort of funding CHD surgery, which is the most pivotal action at present. Flowchart of a patient being funded. Central Message Charitable funding supported approximately 31% of the total hospitalization costs, contributing to an average DALYs averted of 50.82, with a cost-effectiveness of ¥952.19 ($141.27) per DALY averted. Perspective Charitable funding in China alleviates financial barriers to CHD treatment, proving its cost-effectiveness. The demonstrated cost-effectiveness should encourage more organizations to join the effort of funding CHD surgery, which is the most pivotal action at present. Global health initiatives have invested significant resources into maternal and child health, and remarkable success has been obtained, with mortality rates in children younger than age 5 years decreasing by approximately 51% around the globe over the past 20 years.1,2 Congenital heart disease (CHD) is the most common congenital malformation and a major contributor to mortality in children younger than age 5 years.3 It is estimated that 1.3 million children born annually with CHD worldwide, and more than 90% do not receive appropriate cardiac care,4 with the high nominal cost of diagnosis and treatment being among the primary barriers.5, 6, 7, 8 In fact, most patients with CHD can have a favorable prognosis if being treated effectively,9,10 which aligns with the Child Health focus of the World Health Organization.11 Therefore, efforts to alleviate the economic burden of diagnosing and treating patients born with CHD is of paramount importance. Health insurance greatly improves healthcare accessibility, but uncovered out-of-pocket expenses still pose a significant financial burden for the families. For instance, in China, insurance reimbursement rates range from 50% to 70% and vary by regions.12 Notably, the regionalization of medical resources for CHD treatment often requires patients to travel across provinces, causing additional costs.9,13,14 This can lead to delays in care or, in some cases, abandonment of treatment. In recent years, many charitable organizations working in China have begun to focus on the CHD population, actively providing financial assistance.9 However, due to the lack of relevant health economics data, the specific forms, amounts, and proportions of aid may not align with the actual needs of CHD treatment. Therefore, from hospital perspective, our study aims to integrate data from 2759 CHD patients who received such type of funding at Fuwai Hospital between 2012 and 2022. Using health economics data, we analyzed the cost-effectiveness across different groups and proposed potential improvements to future funding model. Methods Design A flowchart of the study design is presented in Figure E1. This study was guided and reported following the Consolidated Health Economic Evaluation Reporting Standards checklist (Table E1).15 Patient Enrollment Patients receiving CHD surgery at Fuwai Hospital from 2012 to 2022 were retrospectively reviewed, and patients who received financial support by nongovernmental organization (NGO) were identified and included in this study. Baseline characteristics, including age, neonate status, gender, weight, use of cardiopulmonary bypass, complexity of CHD, single-ventricle physiology, previous surgery history, length of hospital stay, unexpected reintervention, in-hospital survival status, total expenditure, NGO funding values, and funding percentages were collected. The CHD diagnosis was confirmed by preoperative echocardiography reports and surgical notes according to the International Classification of Disease and Injuries 10th edition. Consistent with our previous studies, mild CHD was defined as isolated atrial septal defect, ventricle septal defect, or patent ductus arteriosus, meanwhile complex CHD was defined as a group of cardiac malformation, including complete atrioventricular septal defect, transposition of the great arteries, tetralogy of Fallot, double-outlet right ventricle, double-outlet left ventricle, pulmonary atresia, truncus arteriosus, total anomalous pulmonary venous connection, Ebstein anomaly, coarctation of the aorta, interrupted aortic arch, hypoplastic right and hypoplastic left heart syndrome, and single ventricle physiology; others were categorized as moderate CHD.5,16 The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery mortality categories were used to risk-stratify the procedures.17 This study was approved by the Ethnic Committee of Fuwai Hospital (2023-2191) and the informed consent requirement was waived due to the retrospective design and the absence of identified data. Inpatients Costs and Funding The total inpatient costs were retrieved from the electronic medical records system as previously described.5 Indirect costs were not included in this study for the hospital perspective. The process of whether a patient could be successfully funded is shown in Figure 1: first, information is acquired about funding programs from multiple sources; second, patients interested in applying for funding visit the charity clinic and 1 or more funding programs are recommended; third, patients and their families complete a series of paperwork and the matched funding program(s) assesses their availability (for severe cases, a patient might receive support from multiple funding programs) and if an initial application is declined, the charity clinic recommends alternative programs; and finally, hospitalization costs are put on account when the patient is discharged. Expenditures covered by the NGOs were used to calculate the cost-effectiveness. All currency is presented as 2022 Chinese yuan (¥) and US dollars ($) with an exchange rate of 6.74 yuan to 1 dollar in 2022 as previously described.5Figure 1Flowchart of patients getting funded. Patients may acquire funding information from multiple sources and then attend a charity clinic. At the clinic, basic information, including planned for surgery recently or not, severity of congenital heart anomalies, and family status, is collected by social workers to match 1 or more potential funding programs. A series of paperwork is required by charitable organizations for availability assessment, including proofs of socioeconomic status, debt, and family members. Once the application approved, the in-hospital expenses will be put on account during discharge, medical bills will be sent to foundation(s), and the approved grant amount will be remitted to our hospital. If a patient is rejected from the initial recommended programs, we may recommend alternative programs for further application. Flowchart of patients getting funded. Patients may acquire funding information from multiple sources and then attend a charity clinic. At the clinic, basic information, including planned for surgery recently or not, severity of congenital heart anomalies, and family status, is collected by social workers to match 1 or more potential funding programs. A series of paperwork is required by charitable organizations for availability assessment, including proofs of socioeconomic status, debt, and family members. Once the application approved, the in-hospital expenses will be put on account during discharge, medical bills will be sent to foundation(s), and the approved grant amount will be remitted to our hospital. If a patient is rejected from the initial recommended programs, we may recommend alternative programs for further application. Cost-Effectiveness Natural history of untreated CHD The natural history of each specific untreated CHD was referenced from a previous publication discussing cost-effectiveness of humanitarian pediatric cardiac surgery in underserved areas of the world,18 which had reviewed the available published data to depict the natural history of most untreated CHD. However, for some rare and untreated complex CHD lacking supporting data, a specialized ad hoc group consisting of 5 senior surgeons and 1 senior cardiologist at our institution reached a consensus on the natural history of rare and untreated complex CHD according to their empirical experience. The natural history of untreated CHD used for calculation is documented in Table E2. Disability-adjusted life years lost due to surgical treatment The age-weighted disability-adjusted life years (DALYs) lost due to surgical treatment for most CHD were derived from published data and an established consensus provided by a group of specialists.18 For rare CHD diagnosis with unavailable data, the DALYs lost after surgical treatment was adjusted to 0.72, referencing the outcome of complex, noncuratively operatable CHD. Remarkably, certain nonanatomical repairs, such as the Fontan procedure, serving as the final physiology with a favorable prognosis for specific single-ventricle patients, were classified as a corrective surgery in this study. Detailed data on DALYs lost due to surgical treatment are provided in Table E3. DALY and DALYs averted According to the World Health Organization, a DALY is a time-based measure defined as a sum of years of life lost due to premature mortality and the years lived with disability.19 The DALYs averted, a significant metric to assess the improvement or deterioration of population health after receiving surgical treatments, was calculated for each patient individually with the following elements: patient's natural history of specific diagnoses (Table E2), DALYs for end-stage heart failure for untreated CHD (equal to 0.35), age at time of surgery, and median life expectancy of a Chinese population in a certain year. For example, for a male patient treated in 2013, the median life expectancy would be set as Chinese male patient in 2013 and for a female patient who was treated in 2021, the median life expectancy would be set as that of a Chinese female patient in 2021, and the DALYs lost due to surgical treatment (Table E3). To identify the cost-effectiveness attributable to the funding support, we multiplied the total cost-effectiveness by the proportion of total expenditure covered by the funding. The formulas used to calculate the DALY averted followed as previously described.18 To test the robustness of our findings, we used the 25th percentile value of DALYs averted among all patients to calculate the cost-effectiveness for each individual patient, and the same assumption was adopted in each subgroup analysis. Statistical Analysis Categorical data were presented as counts with percentage and compared with the χ2 test. Quantitative data were presented as means ± SD and median with interquartile range and compared with the Kruskal-Wallis rank-sum test. All statistical analyses were performed using R version 4.2.2 (R Foundation for Statistical Computing). Results Overall From 2012 to 2022, a total of 2759 patients received CHD surgery and charitable funding were enrolled in this study. Among these participants, 4.13% (114 out of 2759) were neonates, 76.3% (2104 out of 2759) were diagnosed with complex CHD, 7.07% (195 out of 2759) presented with single-ventricle physiology, 28.2% (778 out of 2759) experienced previous heart surgery, and 11.38% (314 out of 2759) underwent an unexpected reintervention. The overall cohort primarily consisted of young children with a median age of 1.58 years and an in-hospital mortality rate of 1.96% (54 out of 2759). The median total hospitalization cost was ¥133,114.04 (USD $19,749.86) with a median of 31% of the costs covered by charitable funding, reaching ¥36,564.34 (USD $5424.98). We found the total expenditure to be cost-effective because it was equivalent to <3 times the per capita Gross National Income for China during 2022 (USD $12,608.00).20,21 Surgical interventions contributed to a median of 50.82 DALYs averted for the overall cohort. The median cost-effectiveness of charitable funding was ¥952.19 (USD $141.27) per DALY averted (Table 1). In the sensitivity analysis, we observed a cost-effectiveness of ¥1618.19 (USD $240.09) per DALY averted (Table E4).Table 1Baseline characteristicsVariableOverall cohort (N = 2759)Age (y)1.58 (0.59-4.72)Male gender1601 (58.03)Neonate114 (4.13)Weight (kg)9.90 (6.80-16.00)Cardiopulmonary bypass2513 (91.08)Complex congenital heart disease2104 (76.3)Single ventricle195 (7.07)Previous surgery778 (28.20)STAT category STAT 1765 (27.73) STAT 2885 (32.08) STAT 3771 (27.94) STAT 4322 (11.67) STAT 516 (0.58)Length of hospital stay (d)22.00 (15.00-35.00)Unexpected reintervention314 (11.38)In-hospital mortality54 (1.96)Total expenditure (¥)133,114.04 (98,045.71-201,427.91)Total expenditure ($)19,749.86 (14,546.84-29,885.45)Funding (¥)36,564.34 (27,911.85-69,036.53)Funding ($)5424.98 (4141.22-10,242.81)Funding percentage (%)31 (18-48)DALYs averted∗50.82 (22.60-59.55)Cost-effectiveness (¥/DALY averted†)952.19 (542.62-1706.38)Cost-effectiveness ($/DALY averted†)141.27 (80.51-253.17)Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Table 1Baseline characteristicsVariableOverall cohort (N = 2759)Age (y)1.58 (0.59-4.72)Male gender1601 (58.03)Neonate114 (4.13)Weight (kg)9.90 (6.80-16.00)Cardiopulmonary bypass2513 (91.08)Complex congenital heart disease2104 (76.3)Single ventricle195 (7.07)Previous surgery778 (28.20)STAT category STAT 1765 (27.73) STAT 2885 (32.08) STAT 3771 (27.94) STAT 4322 (11.67) STAT 516 (0.58)Length of hospital stay (d)22.00 (15.00-35.00)Unexpected reintervention314 (11.38)In-hospital mortality54 (1.96)Total expenditure (¥)133,114.04 (98,045.71-201,427.91)Total expenditure ($)19,749.86 (14,546.84-29,885.45)Funding (¥)36,564.34 (27,911.85-69,036.53)Funding ($)5424.98 (4141.22-10,242.81)Funding percentage (%)31 (18-48)DALYs averted∗50.82 (22.60-59.55)Cost-effectiveness (¥/DALY averted†)952.19 (542.62-1706.38)Cost-effectiveness ($/DALY averted†)141.27 (80.51-253.17)Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Baseline characteristics Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery. Indicates overall disability-adjusted life years (DALYs) averted due to treatment. Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Complexity of CHD Patients diagnosed with complex CHD represented the majority of the cohort (76.3%), with a younger median age (1.50 years) when compared with moderate CHD (2.17 years) and mild CHD (1.59 years). Male patients were predominant in the complex group (60.7%). There were more patients who experienced previous surgeries (29.7%) in this group. Unexpected reinterventions, in-hospital mortality, and DALYs averted were proportionate across CHD types; however, funding percentage was higher for patients with mild CHD compared with others (40% of mild CHD vs 28% of moderate CHD and 32% of complex CHD). As expected, a higher cost-effectiveness was observed in mild CHD, reaching ¥618.86 (USD $91.82) per DALY averted in the main analysis and ¥681.36 (USD $101.09) per DALY averted in the sensitivity analysis. (Table 2 and Table E5).Table 2Difference according to type of congenital heart disease (CHD)VariableMild CHD (N = 80)Moderate CHD (N = 575)Complex CHD (N = 2104)P valueAge (y)1.59 (0.80-4.27)2.17 (0.66-5.85)1.50 (0.57-4.49)<.001Male gender43 (53.8)281 (48.9)1277 (60.7)<.001Neonate0 (0)5 (0.9)109 (5.2)<.001Weight (kg)10.60 (7.50-16.75)11.50 (6.80-18.00)9.60 (6.80-15.15)<.001Cardiopulmonary bypass77 (96.2)552 (96)1884 (89.5)<.001Single ventricle0 (0)0 (0)195 (9.3)<.001Previous surgery7 (8.8)146 (25.4)625 (29.7)<.001STAT category<.001 STAT 165 (81.2)230 (40)470 (22.3) STAT 210 (12.5)272 (47.3)603 (28.7) STAT 34 (5)52 (9)715 (34) STAT 41 (1.2)21 (3.7)300 (14.3) STAT 50 (0)0 (0)16 (0.8)Length of hospital stay (d)13.00 (10.00-20.50)19.00 (13.00-27.00)24.00 (16.00-36.00)<.001Unexpected reintervention7 (8.8)57 (9.9)250 (11.9).316In-hospital mortality2 (2.5)5 (0.9)47 (2.2).105Total expenditure (¥)72,707.90 (60,760.19-121,191.45)111,252.76 (84,363.20-156,296.27)142,292.81 (105,159.96-216,677.35)<.001Total expenditure ($)10,787.52 (9014.86-17,980.93)16,506.34 (12,516.79-23,189.36)21,111.69 (15,602.37-32,147.97)<.001Funding (¥)29,292.45 (25,004.49-36,999.59)31,583.62 (20,105.15-49,432.89)41,421.92 (30,000.00-75,672.62)<.001Funding ($)4346.06 (3709.87-5489.55)4686.00 (2982.96-7334.26)6145.69 (4451.04-11,227.39)<.001Funding percentage (%)40 (23-53)28 (16-44)32 (19-48)<.001DALYs averted∗46.71 (41.27-49.31)47.50 (22.45-59.65)54.42 (22.53-59.62).125Cost-effectiveness (¥/DALY averted†)618.86 (471.81-769.18)697.28 (445.37-1404.77)1079.09 (579.88-1822.75)<.001Cost-effectiveness ($/DALY averted†)91.82 (70.00-114.12)103.45 (66.08-208.42)160.10 (86.04-270.44)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Table 2Difference according to type of congenital heart disease (CHD)VariableMild CHD (N = 80)Moderate CHD (N = 575)Complex CHD (N = 2104)P valueAge (y)1.59 (0.80-4.27)2.17 (0.66-5.85)1.50 (0.57-4.49)<.001Male gender43 (53.8)281 (48.9)1277 (60.7)<.001Neonate0 (0)5 (0.9)109 (5.2)<.001Weight (kg)10.60 (7.50-16.75)11.50 (6.80-18.00)9.60 (6.80-15.15)<.001Cardiopulmonary bypass77 (96.2)552 (96)1884 (89.5)<.001Single ventricle0 (0)0 (0)195 (9.3)<.001Previous surgery7 (8.8)146 (25.4)625 (29.7)<.001STAT category<.001 STAT 165 (81.2)230 (40)470 (22.3) STAT 210 (12.5)272 (47.3)603 (28.7) STAT 34 (5)52 (9)715 (34) STAT 41 (1.2)21 (3.7)300 (14.3) STAT 50 (0)0 (0)16 (0.8)Length of hospital stay (d)13.00 (10.00-20.50)19.00 (13.00-27.00)24.00 (16.00-36.00)<.001Unexpected reintervention7 (8.8)57 (9.9)250 (11.9).316In-hospital mortality2 (2.5)5 (0.9)47 (2.2).105Total expenditure (¥)72,707.90 (60,760.19-121,191.45)111,252.76 (84,363.20-156,296.27)142,292.81 (105,159.96-216,677.35)<.001Total expenditure ($)10,787.52 (9014.86-17,980.93)16,506.34 (12,516.79-23,189.36)21,111.69 (15,602.37-32,147.97)<.001Funding (¥)29,292.45 (25,004.49-36,999.59)31,583.62 (20,105.15-49,432.89)41,421.92 (30,000.00-75,672.62)<.001Funding ($)4346.06 (3709.87-5489.55)4686.00 (2982.96-7334.26)6145.69 (4451.04-11,227.39)<.001Funding percentage (%)40 (23-53)28 (16-44)32 (19-48)<.001DALYs averted∗46.71 (41.27-49.31)47.50 (22.45-59.65)54.42 (22.53-59.62).125Cost-effectiveness (¥/DALY averted†)618.86 (471.81-769.18)697.28 (445.37-1404.77)1079.09 (579.88-1822.75)<.001Cost-effectiveness ($/DALY averted†)91.82 (70.00-114.12)103.45 (66.08-208.42)160.10 (86.04-270.44)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Difference according to type of congenital heart disease (CHD) Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery. Indicates overall disability-adjusted life years (DALYs) averted due to treatment. Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Single-Ventricle Physiology Patients with single-ventricle physiology had a significant higher rate of previous surgeries (47.2%) when compared with 2-ventricle physiology (26.8%) as well as a longer hospital stay (27 vs 22 days; P < .001). The DALYs averted were lower in the single-ventricle physiology patients (22.31 vs 54.16; P < .001). Consequently, repair of patients with 2-ventricle physiology was nearly twice as cost-effective as single-ventricle physiology (¥890.02 per DALY averted vs ¥1627.3 per DALY averted; P < .001). Sensitivity analysis also demonstrated a higher cost-effectiveness in 2-ventricle physiology (¥1594.94 per DALY averted vs ¥1961.28 per DALY averted; P < .001) (Table E6). However, statistical difference was not obtained in funding percentage (Table 3).Table 3Difference according to with or without single-ventricle physiologyVariableTwo-ventricle physiology (n = 2564)Single-ventricle physiology (n = 195)P valueAge, year1.46 (0.56-4.50)4.42 (1.85-6.39)<.001Male gender1466 (57.2)135 (69.2)<.001Neonate114 (4.4)0 (0).005Weight (kg)9.50 (6.60-15.25)15.50 (10.25-19.70)<.001Cardiopulmonary bypass2345 (91.5)168 (86.2).018Previous surgery686 (26.8)92 (47.2)<.001STAT category<.001 STAT 1699 (27.3)66 (33.8) STAT 2817 (31.9)68 (34.9) STAT 3750 (29.3)21 (10.8) STAT 4287 (11.2)35 (17.9) STAT 511 (0.4)5 (2.6)Length of hospital stay (d)22.00 (15.00-34.00)27.00 (18.00-47.00)<.001Unexpected reintervention290 (11.3)24 (12.3).760In-hospital mortality51 (2)3 (1.5).865Total expenditure (¥)132,295.15 (97,668.67-197,913.24)155,211.49 (104,857.70-226,829.21).007Total expenditure ($)19,628.36 (14,490.90-29,363.98)23,028.41 (15,557.52-33,654.19).007Funding (¥)36,564.34 (27,614.61-68,489.45)41,990.54 (31,583.62-75,543.86).018Funding ($)5424.98 (4097.12 to 10,161.64)6230.05 (4686.00-11,208.29).018Funding percentage (%)31 (18-48)33 (20-46).599DALYs averted∗54.16 (22.92-59.66)22.31 (21.12-23.74)<.001Cost-effectiveness (¥/DALY averted†)890.02 (532.41-1643.66)1627.30 (1217.65-2818.21)<.001Cost-effectiveness ($/DALY averted†)132.05 (78.99-243.87)241.44 (180.66-418.13)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Table 3Difference according to with or without single-ventricle physiologyVariableTwo-ventricle physiology (n = 2564)Single-ventricle physiology (n = 195)P valueAge, year1.46 (0.56-4.50)4.42 (1.85-6.39)<.001Male gender1466 (57.2)135 (69.2)<.001Neonate114 (4.4)0 (0).005Weight (kg)9.50 (6.60-15.25)15.50 (10.25-19.70)<.001Cardiopulmonary bypass2345 (91.5)168 (86.2).018Previous surgery686 (26.8)92 (47.2)<.001STAT category<.001 STAT 1699 (27.3)66 (33.8) STAT 2817 (31.9)68 (34.9) STAT 3750 (29.3)21 (10.8) STAT 4287 (11.2)35 (17.9) STAT 511 (0.4)5 (2.6)Length of hospital stay (d)22.00 (15.00-34.00)27.00 (18.00-47.00)<.001Unexpected reintervention290 (11.3)24 (12.3).760In-hospital mortality51 (2)3 (1.5).865Total expenditure (¥)132,295.15 (97,668.67-197,913.24)155,211.49 (104,857.70-226,829.21).007Total expenditure ($)19,628.36 (14,490.90-29,363.98)23,028.41 (15,557.52-33,654.19).007Funding (¥)36,564.34 (27,614.61-68,489.45)41,990.54 (31,583.62-75,543.86).018Funding ($)5424.98 (4097.12 to 10,161.64)6230.05 (4686.00-11,208.29).018Funding percentage (%)31 (18-48)33 (20-46).599DALYs averted∗54.16 (22.92-59.66)22.31 (21.12-23.74)<.001Cost-effectiveness (¥/DALY averted†)890.02 (532.41-1643.66)1627.30 (1217.65-2818.21)<.001Cost-effectiveness ($/DALY averted†)132.05 (78.99-243.87)241.44 (180.66-418.13)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Difference according to with or without single-ventricle physiology Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery. Indicates overall disability-adjusted life years (DALYs) averted due to treatment. Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Neonates A total of 114 neonates received financial support during the study period. There was a higher percentage of neonates in Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery category 4 (24.6%) and unexpected reinterventions (18.4%). Neonates exhibited lower funding support percentage (24% vs 32%), but a statistically higher number of DALYs averted (59.44 vs 50.29; P < .001). Although there was no significance observed between groups in cost-effectiveness, marginal cost-effective value was reached in neonates (Table 4). Sensitivity analysis widened the gap in DALYs averted between neonates and others (40.33 vs 22.52; P < .001), resulting a greater cost-effectiveness for neonates (¥1017.08 vs ¥1623.57 per DALY averted; P < .001) (Table E7).Table 4Difference between neonates and older patientsVariableOthers (n = 2645)Neonates (n = 114)P valueAge (y)1.76 (0.66-4.86)0.04 (0.02-0.05)<.001Male gender1515 (57.3)86 (75.4)<.001Weight (kg)10.00 (7.20-16.00)3.40 (3.00-3.80)<.001Length of hospital stay (d)22.00 (15.00-35.00)23.50 (17.00-32.00).424Cardiopulmonary bypass2414 (91.3)99 (86.8).146STAT category<.001 STAT 1764 (28.9)1 (0.9) STAT 2835 (31.6)50 (43.9) STAT 3737 (27.9)34 (29.8) STAT 4294 (11.1)28 (24.6) STAT 515 (0.6)1 (0.9)Previous surgery777 (29.4)1 (0.9)<.001Single ventricle195 (7.4)0 (0).005Unexpected reintervention293 (11.1)21 (18.4).023In-hospital mortality50 (1.9)4 (3.5).381Total expenditure (¥)131,117.54 (96,840.94-199,846.21)161,159.57 (127,839.27-213,393.25)<.001Total expenditure ($)19,453.64 (14,368.09-29,650.77)23,910.92 (18,967.25-31,660.72)<.001Funding (¥)36,564.34 (28,074.40-68,489.28)42,500.99 (27,600.00-79,289.14).317Funding ($)5424.98 (4165.34-10,161.61)6305.79 (4094.96-11,763.97).317Funding percentage (%)32 (18-48)24 (15- 48).077DALYs averted∗50.29 (22.52-59.49)59.44 (40.33-61.02)<.001Cost-effectiveness (¥/DALY averted†)956.83 (547.30-1718.64)867.10 (492.73-1391.00).052Cost-effectiveness ($/DALY averted†)141.96 (81.20-254.99)128.65 (73.11-206.38).052Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Table 4Difference between neonates and older patientsVariableOthers (n = 2645)Neonates (n = 114)P valueAge (y)1.76 (0.66-4.86)0.04 (0.02-0.05)<.001Male gender1515 (57.3)86 (75.4)<.001Weight (kg)10.00 (7.20-16.00)3.40 (3.00-3.80)<.001Length of hospital stay (d)22.00 (15.00-35.00)23.50 (17.00-32.00).424Cardiopulmonary bypass2414 (91.3)99 (86.8).146STAT category<.001 STAT 1764 (28.9)1 (0.9) STAT 2835 (31.6)50 (43.9) STAT 3737 (27.9)34 (29.8) STAT 4294 (11.1)28 (24.6) STAT 515 (0.6)1 (0.9)Previous surgery777 (29.4)1 (0.9)<.001Single ventricle195 (7.4)0 (0).005Unexpected reintervention293 (11.1)21 (18.4).023In-hospital mortality50 (1.9)4 (3.5).381Total expenditure (¥)131,117.54 (96,840.94-199,846.21)161,159.57 (127,839.27-213,393.25)<.001Total expenditure ($)19,453.64 (14,368.09-29,650.77)23,910.92 (18,967.25-31,660.72)<.001Funding (¥)36,564.34 (28,074.40-68,489.28)42,500.99 (27,600.00-79,289.14).317Funding ($)5424.98 (4165.34-10,161.61)6305.79 (4094.96-11,763.97).317Funding percentage (%)32 (18-48)24 (15- 48).077DALYs averted∗50.29 (22.52-59.49)59.44 (40.33-61.02)<.001Cost-effectiveness (¥/DALY averted†)956.83 (547.30-1718.64)867.10 (492.73-1391.00).052Cost-effectiveness ($/DALY averted†)141.96 (81.20-254.99)128.65 (73.11-206.38).052Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Difference between neonates and older patients Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery. Indicates overall disability-adjusted life years (DALYs) averted due to treatment. Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Previous Surgical History There was a higher proportion of complex CHD (80.3% vs 74.7%; P < .001), single-ventricle physiology (11.8% vs 5.2%; P < .001), and unexpected reintervention (13.8% vs 10.4%; P = .017) among patients who had experienced previous surgery. With similar funding percentage and DALYs averted, charity funding was more cost-effective in patients without previous surgery (¥828.8 per DALY averted) when compared with ¥1349.08 per DALY averted for those with a history of previous surgery (Table 5). Although the sensitivity analysis showed comparable DALYs averted, surgeries for patients without previous surgery remained more cost-effective (¥1525.25 vs ¥2340.61; P < .001) (Table E8).Table 5Difference according to patients with or without previous surgeryVariableWithout previous surgery (n = 1981)With previous surgery (n = 778)P valueAge (y)0.89 (0.46-2.84)4.57 (2.73-6.64)<.001male gender1148 (58.0)453 (58.2).929Neonate113 (5.7)1 (0.1)<.001Weight (kg)8.40 (6.00-12.00)16.00 (12.00-20.70)<.001Cardiopulmonary bypass1771 (89.4)742 (95.4)<.001Complex congenital heart disease1479 (74.7)625 (80.3)<.001Single ventricle103 (5.2)92 (11.8)<.001STAT category<.001 STAT 1478 (24.1)287 (36.9) STAT 2649 (32.8)236 (30.3) STAT 3573 (28.9)198 (25.4) STAT 4267 (13.5)55 (7.1) STAT 514 (0.7)2 (0.3)Length of hospital stay (d)21.00 (14.00-31.00)28.00 (19.00-44.00)<.001Unexpected reintervention207 (10.4)107 (13.8).017In-hospital mortality34 (1.7)20 (2.6).192Total expenditure (¥)121,709.91 (91,892.69-181,881.29)167,022.68 (124,605.67-237,696.83)<.001Total expenditure ($)18,057.85 (13,633.93-26,985.35)24,780.81 (18,487.49-35,266.59)<.001Funding (¥)36,281.93 (27,614.61-60,033.90)53,675.30 (31,583.62-88,438.99)<.001Funding ($)5383.08 (4097.12-8907.11)7963.70 (4686.00-13,121.51)<.001Funding percentage (%)31 (18-47)31 (18-49).810DALY averted∗52.20 (22.93-59.45)39.95 (22.06-60.41).128Cost-effectiveness (¥/DALY averted†)828.80 (529.87-1521.81)1349.08 (635.66-2627.34)<.001Cost-effectiveness ($/DALY averted†)122.97 (78.62-225.79)200.16 (94.31-389.81)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Table 5Difference according to patients with or without previous surgeryVariableWithout previous surgery (n = 1981)With previous surgery (n = 778)P valueAge (y)0.89 (0.46-2.84)4.57 (2.73-6.64)<.001male gender1148 (58.0)453 (58.2).929Neonate113 (5.7)1 (0.1)<.001Weight (kg)8.40 (6.00-12.00)16.00 (12.00-20.70)<.001Cardiopulmonary bypass1771 (89.4)742 (95.4)<.001Complex congenital heart disease1479 (74.7)625 (80.3)<.001Single ventricle103 (5.2)92 (11.8)<.001STAT category<.001 STAT 1478 (24.1)287 (36.9) STAT 2649 (32.8)236 (30.3) STAT 3573 (28.9)198 (25.4) STAT 4267 (13.5)55 (7.1) STAT 514 (0.7)2 (0.3)Length of hospital stay (d)21.00 (14.00-31.00)28.00 (19.00-44.00)<.001Unexpected reintervention207 (10.4)107 (13.8).017In-hospital mortality34 (1.7)20 (2.6).192Total expenditure (¥)121,709.91 (91,892.69-181,881.29)167,022.68 (124,605.67-237,696.83)<.001Total expenditure ($)18,057.85 (13,633.93-26,985.35)24,780.81 (18,487.49-35,266.59)<.001Funding (¥)36,281.93 (27,614.61-60,033.90)53,675.30 (31,583.62-88,438.99)<.001Funding ($)5383.08 (4097.12-8907.11)7963.70 (4686.00-13,121.51)<.001Funding percentage (%)31 (18-47)31 (18-49).810DALY averted∗52.20 (22.93-59.45)39.95 (22.06-60.41).128Cost-effectiveness (¥/DALY averted†)828.80 (529.87-1521.81)1349.08 (635.66-2627.34)<.001Cost-effectiveness ($/DALY averted†)122.97 (78.62-225.79)200.16 (94.31-389.81)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Difference according to patients with or without previous surgery Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery. Indicates overall disability-adjusted life years (DALYs) averted due to treatment. Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Unexpected Reintervention Patients who had an unexpected reintervention were mostly neonates (6.7% vs 3.8%; P = .023), experienced longer hospital stay (44 vs 21 days; P < .001), and had a higher in-hospital mortality rate (9.6% vs 1.0%; P < .001). With similar DALYs averted, patients who received unexpected reintervention had a lower funding percentage (19% vs 33%; P < .001) and a lower cost-effectiveness (¥1303.98 per DALY averted vs ¥919.12 per DALY averted; P < .001) (Table 6). Sensitivity analysis also supported these findings (Table E9).Table 6Difference between patients with or without unexpected reinterventionVariableWithout reintervention (n = 2445)With reintervention (n = 314)P valueAge (y)1.58 (0.61-4.72)1.58 (0.49-4.72).307Male gender1431 (58.5)170 (54.1).155Neonate93 (3.8)21 (6.7).023Weight (kg)10.00 (7.00-16.00)9.60 (6.20-15.50).131Length of hospital stay (d)21.00 (14.0-31.00)44.00 (30.00-70.00)<.001Cardiopulmonary bypass2225 (91)288 (91.7).753STAT category.001 STAT 1700 (28.6)65 (20.7) STAT 2793 (32.4)92 (29.3) STAT 3654 (26.7)117 (37.3) STAT 4284 (11.6)38 (12.1) STAT 514 (0.6)2 (0.6)Complex congenital heart disease1854 (75.8)250 (79.6).316Single ventricle171 (7)24 (7.6).760Previous surgery671 (27.4)107 (34.1).017Total expenditure (¥)124,816.51 (94,545.26-173,616.61)307,035.32 (214,216.37-504,135.46)<.001Total expenditure ($)18,518.77 (14,027.49-25,759.14)45,554.20 (31,782.84-74,797.55)<.001Funding (¥)36,564.34 (27,614.61-64,272.48)61,460.68 (33,494.22-103,284.13)<.001Funding ($)5424.98 (4097.12-9535.98)9118.80 (4969.47-15,324.06)<.001Funding percentage (%)33 (20-49)19 (10-31)<.001In-hospital mortality24 (1)30 (9.6)<.001DALY averted∗50.90 (22.72-59.53)50.53 (21.47-59.84).100Cost-effectiveness (¥/DALY averted†)919.12 (541.98-1643.58)1303.98 (565.65-2628.14)<.001Cost-effectiveness ($/DALY averted†)136.37 (80.41-243.85)193.47 (83.92-389.93)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Table 6Difference between patients with or without unexpected reinterventionVariableWithout reintervention (n = 2445)With reintervention (n = 314)P valueAge (y)1.58 (0.61-4.72)1.58 (0.49-4.72).307Male gender1431 (58.5)170 (54.1).155Neonate93 (3.8)21 (6.7).023Weight (kg)10.00 (7.00-16.00)9.60 (6.20-15.50).131Length of hospital stay (d)21.00 (14.0-31.00)44.00 (30.00-70.00)<.001Cardiopulmonary bypass2225 (91)288 (91.7).753STAT category.001 STAT 1700 (28.6)65 (20.7) STAT 2793 (32.4)92 (29.3) STAT 3654 (26.7)117 (37.3) STAT 4284 (11.6)38 (12.1) STAT 514 (0.6)2 (0.6)Complex congenital heart disease1854 (75.8)250 (79.6).316Single ventricle171 (7)24 (7.6).760Previous surgery671 (27.4)107 (34.1).017Total expenditure (¥)124,816.51 (94,545.26-173,616.61)307,035.32 (214,216.37-504,135.46)<.001Total expenditure ($)18,518.77 (14,027.49-25,759.14)45,554.20 (31,782.84-74,797.55)<.001Funding (¥)36,564.34 (27,614.61-64,272.48)61,460.68 (33,494.22-103,284.13)<.001Funding ($)5424.98 (4097.12-9535.98)9118.80 (4969.47-15,324.06)<.001Funding percentage (%)33 (20-49)19 (10-31)<.001In-hospital mortality24 (1)30 (9.6)<.001DALY averted∗50.90 (22.72-59.53)50.53 (21.47-59.84).100Cost-effectiveness (¥/DALY averted†)919.12 (541.98-1643.58)1303.98 (565.65-2628.14)<.001Cost-effectiveness ($/DALY averted†)136.37 (80.41-243.85)193.47 (83.92-389.93)<.001Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery.∗Indicates overall disability-adjusted life years (DALYs) averted due to treatment.†Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Difference between patients with or without unexpected reintervention Values are presented as median (interquartile range) and n (%). All currency is presented as 2022 Chinese yuan (¥) and is exchanged to 2022 USD with an exchange rate of 6.74 retrieved from the World Bank. STAT, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery. Indicates overall disability-adjusted life years (DALYs) averted due to treatment. Indicates cost-effectiveness due to charitable funding, with the calculation of overall cost-effectiveness times funding percentage. Discussion To our knowledge, this is the first cost-effectiveness analysis with the largest cohort of a CHD population to delineate the current profile of charitable funding of congenital heart surgery in China. Four major findings are presented: overall, charitable funding supported approximately 31% of the total hospitalization costs, contributing to an average of 50.82 DALYs averted and a cost-effectiveness of ¥952.19 ($141.27) per DALY averted; funding percentage was lower in neonates, patients with complex CHD, and those requiring unexpected reintervention; the DALYs averted were significantly higher for neonates but lower in patients with single-ventricle physiology; patients with complex CHD, single-ventricle physiology, previous surgery, and unexpected reintervention exhibited a lower cost-effectiveness (Figure 2).Figure 2Charitable funding of congenital heart surgery in China: A cost-effectiveness analysis from the Chinese National Center for Cardiovascular Diseases. CHD, Congenital heart disease; NGO, nongovernmental organization; DALY, disability-adjusted life years. Charitable funding of congenital heart surgery in China: A cost-effectiveness analysis from the Chinese National Center for Cardiovascular Diseases. CHD, Congenital heart disease; NGO, nongovernmental organization; DALY, disability-adjusted life years. Humanitarian assistance for patients with CHD has been reported to improve the life expectancy, quality of life, and significantly alleviate the financial burden of families and societies.18,22,23 Since 2012, charitable funding has supported a total of 2759 patients with CHD in our hospital and covered approximately 31% of hospitalization costs for each patient, partly relieving the economic stress of families with CHD patients. Nowadays, both government and NGOs are struggling for the humanitarian assistance to children and adolescents in the fields of health, nutrition, protection, and education to promote the well-rounded development of those patients.23, 24, 25 Despite CHD being the most common cardiovascular disease in children,3 available humanitarian programs remain limited. Our findings justify the cost-effectiveness of humanitarian support in congenital heart surgery and may enhance the confidence of NGOs to increase aid for CHD, ultimately reducing the economic burden and associated DALYs faced by CHD population. In our center, funding percentage for neonates, patients with complex CHD, and unexpected reintervention were relatively low, which may be explained by the higher expenses of treatment courses according to our previous study.5 The current funding model adopted by NGOs in our center is solely based on diagnosis, so the amount of support per eligible patient is relatively fixed, and only a small subset of children with exceptional clinical events or socioeconomic circumstances can receive additional support at charities’ discretion. As a result, the proportion of total costs covered by funding support is lower in these patients, albeit with a higher absolute amount of funding. In future, charitable organizations should adopt a more comprehensive funding strategy that considers not only diagnosis but also age group and planned surgical strategy when determining the funding amount. The DALYs averted were higher for neonates due to the advances in neonatal cardiac surgery,26,27 but lower in patients with single-ventricle physiology. While considering the economic influence of a charitable support program for patients with CHD should be a part of the equation, we must be careful not to fall into the utilitarian ethical trap that would bias us into believing that support should be only directed toward neonatal surgery to the detriment of other less-rewarding diagnoses (eg, single-ventricle physiology). Patients with single-ventricle physiology are older and have experienced multiple open-heart surgeries, such as unidirectional Glenn, bidirectional Glenn, and eventually Fontan completion.28 Older age at the final surgical stage and increased total number of open-heart surgery led to the reduced DALYs averted compared with other patients who underwent 1-stage repair surgery.29 However, lower DALYs averted does not indicate meaningless or unworthy of support. The true value of cost-effectiveness analysis is not in the comparison between neonates and older patients, but between patients with surgery versus without surgery. When we see it from this perspective and realize the enormous amount of DALYs lost to the natural history of CHD, the decision to support as many patients as possible becomes not only economically justifiable, but also ethically sound. In our center, approximately 90% of applicants were approved for funding support. When an application is rejected by the recommended programs, patients may be referred to alternative programs within our charitable networks (Figure 1), which may improve the overall likelihood of receiving funding. However, other medical centers may be unable to achieve similarly high approval rates of support due to the limited collaborating charitable associations. As the regionalization of CHD treatment continues to intensify,10 tertiary centers are likely to face an even heavier burden, leading to a higher demand for financial assistance. Therefore, an important objective of this study was to demonstrate the cost-effectiveness of charitable funding of congenital heart surgery in China, thereby encouraging more organizations to join the effort of funding congenital heart surgery, which is the most pivotal action at present. There were several limitations in this study that should be addressed. First, the retrospective nature of this study rather than a prospective design may limit its scope and in-depth analysis. Second, only the direct costs of hospitalization were considered for this study, whereas the indirect costs (eg, travel, accommodation, and income lost) could not be captured with the available data. Accordingly, our analysis should be interpreted as reflecting costs and cost-effectiveness from a hospital perspective, and the estimation of indirect costs requires further investigations. Third, this single-center study may represent the hospitalization expenditure and charitable funding in medically advantaged regions, so potential selection bias may occur and generalization of the finding to remote regions should be cautious and future multicenter investigation is warranted. Conclusions Over the past decade, charitable funding in China has alleviated the financial burden on families of patients with CHD. We suggest refining the funding models to incorporate more comprehensive considerations, going beyond a mere focus on diagnosis to reach a final decision. The demonstrated cost-effectiveness in funding congenital heart surgery should encourage more organizations to participate in this cause, allowing more CHD patients to receive support. Availability of Data and Material Data used in this manuscript could be acquired at reasonable request to corresponding author. Data Sharing Statement De-identified data used in this study could be obtained via reasonable request. Conflict of Interest Statement The authors reported no conflicts of interests. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.